SCHEMBL2175496

SCHEMBL2175496

CC(C)CCCCCCCCCCC[C]=O

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.43
KDM4C Q9H3R0 2/20 0.33
TRPV1 Q8NER1 1/20 0.33
KDM4A O75164 1/20 0.33
PHF8 Q9UPP1 1/20 0.33
KDM2A Q9Y2K7 1/20 0.33
TRPA1 O75762 1/20 0.33
BLM P54132 1/20 0.32
HIF1A Q16665 1/20 0.32
EPAS1 Q99814 1/20 0.32
MEN1 O00255 1/20 0.30
USP2 O75604 1/20 0.30
ALDH1A1 P00352 1/20 0.30
TP53 P04637 1/20 0.30
CYP3A4 P08684 1/20 0.30
MAPT P10636 1/20 0.30
MAPK1 P28482 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1827462 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL1985823 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL2176899 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL2177991 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL2174526 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL132521 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL2173439 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL536857 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL443449 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8
SCHEMBL294141 1.00 LMNA (0.43) LMNAKDM4CTRPV1KDM4APHF8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2946795-B1 TISSUE ADHESIVE AND PROCESS FOR PRODUCING SAME NAT INST MATERIALS SCIENCE (JP) 2019-04-17 EP claimed
US-10064973-B2 Tissue adhesive and method for producing same NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) 2018-09-04 US claimed
US-20150359924-A1 TISSUE ADHESIVE AND METHOD FOR PRODUCING SAME NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) 2015-12-17 US claimed
EP-2946795-A1 TISSUE ADHESIVE AND PROCESS FOR PRODUCING SAME National Institute for Materials Science (JP) 2015-11-25 EP claimed
US-4785012-A OXAZOLE DERIVATIVES CONTAINING ALCOHOLS OR ESTERS SYNTEX CORPORATION (US) 1988-11-15 US claimed
WO-2024014310-A1 COMPOSITION COMPRISING SKIN CARE ACTIVE INGREDIENT OR CELLULOSE COMPOUND L'OREAL (FR) 2024-01-18 WO disclosed
WO-2024014311-A1 COSMETIC COMPOSITION COMPRISING SELECTED OIL AND DIOL L'OREAL (FR) 2024-01-18 WO disclosed
US-10670997-B2 Intermediate transfer body, method for manufacturing intermediate transfer body, and image forming device Konica Minolta, Inc. (JP) 2020-06-02 US disclosed
US-20200081376-A1 INTERMEDIATE TRANSFER BODY, METHOD FOR MANUFACTURING INTERMEDIATE TRANSFER BODY, AND IMAGE FORMING DEVICE Konica Minolta, Inc. (JP) 2020-03-12 US disclosed
EP-2946795-B1 TISSUE ADHESIVE AND PROCESS FOR PRODUCING SAME NAT INST MATERIALS SCIENCE (JP) 2019-04-17 EP disclosed
US-10064973-B2 Tissue adhesive and method for producing same NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) 2018-09-04 US disclosed
US-20150359924-A1 TISSUE ADHESIVE AND METHOD FOR PRODUCING SAME NATIONAL INSTITUTE FOR MATERIALS SCIENCE (JP) 2015-12-17 US disclosed
EP-2946795-A1 TISSUE ADHESIVE AND PROCESS FOR PRODUCING SAME National Institute for Materials Science (JP) 2015-11-25 EP disclosed
US-7973145-B2 Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same TOYO SUISAN KAISHA, LTD. (JP) 2011-07-05 US disclosed
US-20100298246-A1 Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same TOYO SUISAN KAISHA, LTD. (JP) 2010-11-25 US disclosed
US-20090209475-A1 Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same TOYO SUISAN KAISHA, LTD. (JP) 2009-08-20 US disclosed
WO-2005014528-A1 STRAIGHT-CHAIN AND BRANCHED-CHAIN LIPID COMPOUNDS AS SELECTIVE INHIBITORS OF CYCLOOXYGENASE-2, ANTI-INFLAMMATORY AGENTS, AND ANTI-CANCER AGENTS YANG ZHENHUA (US) 2005-02-17 WO disclosed
US-4785012-A OXAZOLE DERIVATIVES CONTAINING ALCOHOLS OR ESTERS SYNTEX CORPORATION (US) 1988-11-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298246-A1 Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same SLC5A2, SLC5A1, DEGS1 LMNA 3304/4885KDM4C 2335/4885TRPV1 1543/4885
US-20090209475-A1 Sulfonated sugar compounds, pharmaceutical compositions which contain the same, and methods of treating tumors with the same SLC5A2, SLC5A1, DEGS1 LMNA 3304/4885KDM4C 2335/4885TRPV1 1543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.